title: A randomized, double-masked controlled clinical trial of Sandostatin long-acting release depot in patients with postsurgical cystoid macular edema.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the safety and efficacy of octreotide, a somatostatin analog, for treatment of postsurgical cystoid macular edema.
  
  
  METHODS
  Twenty-one patients with chronic, refractory postsurgical cystoid macular edema and Early Treatment Diabetic Retinopathy Study best-corrected visual acuity of 20/25 to 20/400 were randomized 2:1 to 30 mg monthly intramuscular octreotide or placebo. Outcome measures were visual acuity (primary) and macular thickness and fluorescein angiographic leakage (secondary).
  
  
  RESULTS
  Fourteen eyes received octreotide and seven eyes received placebo. Mean duration of cystoid macular edema was 2.65 and 1.99 years for Sandostatin long-acting release and placebo groups, respectively. Visual acuity at 6 months improved > or =2 lines in 7 of 14 eyes (50%) in the treatment group and 0 of 7 eyes in the placebo group (P = 0.046). Improvement in retinal thickening and angiographic leakage occurred in 3 of 13 eyes (23.1%) and 3 of 14 eyes (21.4%) of the treatment group, respectively, and in 1 of 7 eyes (14.3%) (P = 1.0 compared with the treatment group) and 0 of 7 eyes in the placebo group (P = 0.52 compared with the treatment group). The three eyes that improved in all parameters were treated with octreotide.
  
  
  CONCLUSIONS
  Although there were no statistically significant differences between both groups in retinal thickening or angiographic leakage, octreotide-treated patients were more likely to experience a > or =2-line improvement in visual acuity. However, this observation cannot be generalized because of the small sample size.
authors.affiliation: Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
authors.forename: Syed Mahmood Ali
authors.initials: SM
authors.lastname: Shah
authors.forename: Quan Dong
authors.initials: QD
authors.lastname: Nguyen
authors.forename: Hafsa Syyida
authors.initials: HS
authors.lastname: Mir
authors.forename: Antonio
authors.initials: A
authors.lastname: Polito
authors.forename: Gulnar
authors.initials: G
authors.lastname: Hafiz
authors.forename: Sinan
authors.initials: S
authors.lastname: Tatlipinar
authors.forename: Diana V
authors.initials: DV
authors.lastname: Do
authors.forename: Susan
authors.initials: S
authors.lastname: Vitale
authors.forename: Julia A
authors.initials: JA
authors.lastname: Haller
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D002908:Chronic Disease; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007273:Injections, Intramuscular; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D011183:Postoperative Complications; D011446:Prospective Studies; D012160:Retina / Q000473:pathology; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D015282:Octreotide